OM Pharma

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections and is also active in the treatment of vascular diseases. It operates worldwide through a strong network of international partners and invests its profits in R&D to develop microbial derived immunotherapeutic products to treat acute and chronic immunological disorders resulting from inflammation and infections. The company strives to improve the quality of life of patients around the world by providing access to better treatment of immunological imbalances. For more information, visit the website: www.ompharma.com

Salus Group / Skupina Salus

Salus Group is the leading commercialization and distribution partner of choice for Healthcare and Biotech companies seeking to expand their presence and drive business growth in 17 countries across Central Eastern and South Eastern Europe. Our mission is to address the unmet medical needs in the CEE/SEE region by bringing innovative medical treatments to patients. With over 50 years of experience and a deep understanding of the regional market, we leverage our extensive network to deliver successful access commercialization results. At Salus Group, we are passionate about putting our customers and patients first, and we strive to provide exceptional service and support to meet their needs. Our comprehensive range of services includes market access, medical, promotion, sales, regulatory, pharmacovigilance, NPP, distribution, warehousing - all coordinated from one location in EU Slovenia, Salus' HQ. With a focus on scientific expertise and a commitment to excellence, we are dedicated to shaping the future of healthcare in the CEE region. Contact us: Email: razvoj@salus.si Telephone: +386 1 589 10 00 Website: www.salus.si

Costello Medical

At Costello Medical, we enjoy building lasting partnerships in the healthcare sector by providing exceptional service. Our vision is to be a leading global partner consistently striving for meaningful and outstanding contributions that improve people’s health and lives. Our experts support the healthcare sector in the analysis, interpretation, and communication of clinical and health economic data; our service offerings include evidence development, statistics, health economics, HTA, real-world evidence, market access, medical affairs, publications, and design. We are one of the most established independent agencies delivering medical communications and health economic services. We have grown organically since foundation in 2008 to a team of over 350 based in Cambridge, London, Manchester and Bristol in the UK and internationally in Singapore, China and the US. Our talented team has experience with a variety of leading pharmaceutical and device companies across an extensive range of therapy areas and geographies, including Europe, Asia Pacific, and North America. We are proud to have achieved a 3-star accreditation with Best Companies™ for a sixth consecutive year, and have achieved B Corp certification, showing that we meet the highest standards of verified social and environmental performance.

Eurofins BioPharma Product Testing Netherlands

Eurofins BioPharma Product Testing Netherlands is part of the Eurofins’ international network of harmonised product testing laboratories. We have over 20 years of experience serving the (bio)pharmaceutical and medical device industry with laboratory, manufacturing and consultancy services. Our laboratories offer a broad range of methodologies under GMP authorisation, GLP, and ISO 17025, 9001, and 13485 accreditations. Our services are fully comprehensive and include testing of drug substances, final products, intermediates, starting raw materials for both small molecule and biologics drug products, and medical devices. We can support our customers with developing test methods from scratch or transfer client methods under regulatory compliant conditions. Aside from testing, we have multiple aseptic manufacturing units for small-scale compounding and fill & finish activities, including labelling and packaging services. Leveraging our international network of Eurofins companies, we can offer our customers the complete testing package for their product while ensuring regulatory compliance.

Entourage Health

Entourage Health Corp. (previously WeedMD Inc.) is the publicly traded parent company of Entourage Brands Corp. (formerly WeedMD RX Inc.) and CannTx Life Sciences Inc., licence holders and producers of cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, Ontario as well as a fully-licensed 26,000 sq. ft. Aylmer, Ontario-based extraction, processing and distribution facility. With the addition of Starseed Medicinal, a medical-centric brand, WeedMD has expanded its multi-channeled distribution strategy. Starseed’s industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, along with other employers and union groups complements WeedMD’s direct sales to medical patients. In October 2021, Entourage acquired craft cultivator CannTx Life Sciences which operates out of its state-of-the-art micropropagation and specialty extraction facility in Guelph, Ontario. Craft brand Royal City Cannabis was added to Entourage’s elite adult-use product portfolio that includes Color Cannabis and Saturday Cannabis - sold across eight provincial distribution agencies. The Company maintains strategic relationships in the seniors’ market and supply agreements with Shoppers Drug Mart. It is also the exclusive Canadian producer and distributor of award-winning, U.S.-based wellness brand Mary's Medicinals. Entourage is currently collaborating with a subsidiary of The Boston Beer Company to launch cannabis-infused beverages in Canada in 2022. Our team of experienced growers, scientists and qualified professionals are committed to providing the quality medical-grade products to patients and consumers across Canada. Entourage is listed on the TSX-V under the symbol ENTG and in the U.S. via OTCQX:ETRGF and Frankfurt market, FSE:4WE.